Enabling rheumatology practices to use complex administration codes for biologic drugs is critical for maintaining patient access to essential therapies.
In 1916, a handful of conservation advocates successfully lobbied Congress to create the National Park Service, which now protects more than 85 million acres of U.S. land. Dedicated rheumatology advocacy has lasting effects, too, as evidenced by several policy wins in 2021 and efforts underway for 2022.
States increasingly take the lead on issues critical to our members and the field of rheumatology, including copay accumulator bans, white bagging restrictions, prior authorization and drug pricing.
A new law in Texas establishes a continuous prior authorization exemption for physicians who earn a 90% approval rate on prior authorization requests for a given service over a period of six months.
Updated Dec. 16, 2021: In response to advocacy from the ACR and other provider and patient groups, Congress passed legislation to avoid the nearly 10% “Medicare cliff” scheduled to take effect Jan 1. The ACR thanks all ACR/ARP members and patients who took the time to engage in this critical effort with us to protect…
The ACR has long supported efforts to reduce drug prices through many of the provisions included in the House-passed version of the Build Back Better Act. However, the current wording of one provision puts patient access to Medicare Part B treatments at risk.
With a record-high 46 first-time contributors, this year’s matching campaign raised more than $26,000 from members and another $17,000 from volunteer leaders who made a pledge for each donor, advancing advocacy efforts on behalf of rheumatology.
After a year marked with rheumatology gains in evaluation and management valuation, as well as quality reporting, ongoing ACR efforts target impending Medicare reimbursement cuts and other practice challenges.